---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-22-000035"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2022-03-14T23:59:59+00:00"
generated_at: "2026-06-26T23:20:26.561385+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sema4 reports Q4 revenue $57.8M, restates prior-period financials due to expense classification errors

## Summary
- Q4 2021 revenue $57.8M (up 24% ex-COVID); full-year revenue $212.2M. Net loss $40.2M Q4, $245.4M full year.
- Test volumes (ex-COVID) grew 37% YoY to 82,966; Oncology volumes up 142%, Women's Health up 33%.
- Restating audited financials for 2020 and 2019, and unaudited quarters in 2021/2020, due to expense misclassification and out-of-period cost recognition.
- 2022 guidance: total revenue $215-225M, test volume growth >20% ex-COVID, adjusted gross margin >10%; excludes pending GeneDx acquisition.
- Cash $400.6M at Dec 31, 2021; pending $200M PIPE and GeneDx acquisition expected to close Q2 2022.

## SEC filing metadata
- accession: 0001818331-22-000035
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2022-03-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 4.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000035/0001818331-22-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833122000035/smfr-20220310.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-22-000035
- JSON: https://secwatch.observer/filing/0001818331-22-000035.json
- Plain text: https://secwatch.observer/filing/0001818331-22-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.